NCT01264367

A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Bukwang Pharmaceutical · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

A study to evaluate the efficacy and safety of clevudine and peg-interferon in sequence compared with clevudine alone in the patients with HBeAg(+) chronic Hepatitis B or clevudine and peg-interferon sequential treatment in patients with chronic Hepatitis B who have HBeAg(+)

Conditions

• HBeAg(+) Chronic Hepatitis B

Interventions

Type	Name	Description
DRUG	Clevudine	30mg,QD
DRUG	Clevudine + Peg-interferon	30mg, QD(for 24 weeks) + 180mcg,QW(for 24 weeks)

Timeline

• Start date: 2008-12-01
• Primary completion: 2013-08-01
• Completion: 2014-05-01
• First posted: 2010-12-21
• Last updated: 2014-12-18

Locations

1 site across 1 country: South Korea